Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Enriched Environment Attenuates Enhanced Trait Anxiety in Association with Normalization of Aberrant Neuro-Inflammatory Events.

Tytuł:
Enriched Environment Attenuates Enhanced Trait Anxiety in Association with Normalization of Aberrant Neuro-Inflammatory Events.
Autorzy:
Sah A; Department of Pharmacology and Toxicology, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80-82/III, A-6020 Innsbruck, Austria.
Rooney S; Department of Pharmacology and Toxicology, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80-82/III, A-6020 Innsbruck, Austria.
Kharitonova M; Department of Pharmacology and Toxicology, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80-82/III, A-6020 Innsbruck, Austria.
Sartori SB; Department of Pharmacology and Toxicology, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80-82/III, A-6020 Innsbruck, Austria.
Wolf SA; Cellular Neurocience, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.; Department of Experimental Ophthalmology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Singewald N; Department of Pharmacology and Toxicology, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80-82/III, A-6020 Innsbruck, Austria.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Oct 27; Vol. 23 (21). Date of Electronic Publication: 2022 Oct 27.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Anxiety*/drug therapy
Microglia*
Animals ; Mice ; Humans ; Adult ; Anxiety Disorders ; Disease Models, Animal ; Minocycline/pharmacology ; Minocycline/therapeutic use ; Hippocampus
References:
Transl Psychiatry. 2012 Oct 16;2:e171. (PMID: 23047242)
Physiol Behav. 2017 Feb 1;169:130-140. (PMID: 27876639)
Brain Behav Immun. 2016 Nov;58:261-271. (PMID: 27474084)
Nat Neurosci. 2006 Feb;9(2):268-75. (PMID: 16415867)
Mol Psychiatry. 2014 Jun;19(6):699-709. (PMID: 24342992)
Biomed Res Int. 2017;2017:5071786. (PMID: 29181395)
Sci Total Environ. 2010 May 15;408(12):2600-7. (PMID: 20299076)
Transl Psychiatry. 2014 Feb 11;4:e359. (PMID: 24518397)
J Neurosci. 2013 Oct 9;33(41):16262-7. (PMID: 24107957)
Neurosci Biobehav Rev. 2015 Feb;49:19-31. (PMID: 25449533)
CNS Neurol Disord Drug Targets. 2013 Aug;12(5):587-92. (PMID: 23574171)
J Neuroimmunol. 2019 Jun 15;331:87-96. (PMID: 28844503)
J Lipid Res. 2011 Aug;52(8):1542-50. (PMID: 21572087)
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 2;76:88-100. (PMID: 28288856)
Brain Behav Immun. 2016 Mar;53:242-254. (PMID: 26724574)
Front Cell Neurosci. 2016 Jun 28;10:169. (PMID: 27445696)
Pharmacol Biochem Behav. 2020 Oct;197:172993. (PMID: 32659243)
Pharmacol Ther. 2019 Dec;204:107402. (PMID: 31470029)
J Neurosci. 2013 Mar 6;33(10):4216-33. (PMID: 23467340)
Environ Res. 2022 Dec;215(Pt 1):114181. (PMID: 36113572)
Neuropharmacology. 2012 Jan;62(1):304-12. (PMID: 21835188)
Neuron. 2013 Jul 10;79(1):16-29. (PMID: 23849196)
Transl Psychiatry. 2019 Sep 13;9(1):223. (PMID: 31519869)
Front Neurosci. 2020 Jun 12;14:605. (PMID: 32655354)
Int J Environ Res Public Health. 2018 Oct 10;15(10):. (PMID: 30308972)
Front Public Health. 2021 Nov 25;9:758457. (PMID: 34900906)
J Neuroimmune Pharmacol. 2017 Jun;12(2):277-291. (PMID: 27730347)
Mol Psychiatry. 2021 Jun;26(6):2533-2552. (PMID: 33473150)
Focus (Am Psychiatr Publ). 2017 Apr;15(2):199-210. (PMID: 31997971)
Depress Anxiety. 2017 Mar;34(3):267-280. (PMID: 28060463)
Environ Res. 2018 Oct;166:458-465. (PMID: 29940479)
Metab Brain Dis. 2018 Aug;33(4):1281-1292. (PMID: 29704081)
J Neurosci Res. 2017 Aug;95(8):1602-1610. (PMID: 27862185)
Proc Natl Acad Sci U S A. 2018 May 15;115(20):5259-5264. (PMID: 29712842)
Nat Rev Neurosci. 2019 Apr;20(4):235-245. (PMID: 30723309)
Trends Neurosci. 2015 Oct;38(10):637-658. (PMID: 26442697)
Sci Rep. 2020 Aug 20;10(1):14053. (PMID: 32820184)
J Neurosci. 2021 Mar 31;41(13):2899-2910. (PMID: 33637561)
Neurosci Lett. 2019 Apr 17;698:51-57. (PMID: 30615977)
Eur J Neurosci. 2020 Nov;52(9):4081-4099. (PMID: 32726468)
Proc Natl Acad Sci U S A. 2016 May 31;113(22):E3130-9. (PMID: 27185913)
Trends Neurosci. 2010 Dec;33(12):569-79. (PMID: 20961627)
Appl Psychol Health Well Being. 2022 Aug;14(3):1037-1061. (PMID: 35259287)
Brain Behav Immun. 2015 Nov;50:275-287. (PMID: 26209808)
Lancet. 2021 Nov 6;398(10312):1700-1712. (PMID: 34634250)
Neurosci Biobehav Rev. 2018 Apr;87:27-37. (PMID: 29407523)
J Neurochem. 2016 Oct;139 Suppl 2:136-153. (PMID: 26990767)
Brain Behav Immun. 2012 Mar;26(3):500-10. (PMID: 22281279)
Int J Neuropsychopharmacol. 2019 Apr 1;22(4):317-328. (PMID: 30668714)
Metab Brain Dis. 2014 Mar;29(1):93-104. (PMID: 24318482)
Curr Opin Pharmacol. 2020 Feb;50:88-95. (PMID: 32007727)
Environ Res. 2018 Feb;161:129-135. (PMID: 29136521)
Brain Res Bull. 2017 Jun;132:150-159. (PMID: 28552674)
Neuropsychopharmacology. 2017 Jan;42(1):254-270. (PMID: 27510423)
J Neuroinflammation. 2018 Jan 17;15(1):21. (PMID: 29343269)
Cell Tissue Res. 2011 Jul;345(1):69-86. (PMID: 21688212)
Int J Dev Neurosci. 2018 Jun;67:19-32. (PMID: 29545098)
Psychoneuroendocrinology. 2018 Sep;95:43-49. (PMID: 29800779)
J Neurosci. 2019 Aug 21;39(34):6766-6780. (PMID: 31217332)
Neuropharmacology. 2019 Feb;145(Pt A):59-74. (PMID: 29630903)
Biol Direct. 2021 Aug 5;16(1):12. (PMID: 34353376)
Br J Pharmacol. 2022 Apr;179(8):1640-1660. (PMID: 34076891)
Glia. 2014 Jul;62(7):1176-94. (PMID: 24723305)
Behav Brain Res. 2021 Feb 5;399:112998. (PMID: 33197458)
Front Cell Neurosci. 2014 Apr 03;8:97. (PMID: 24772064)
Front Pharmacol. 2019 Jun 13;10:683. (PMID: 31263417)
Transl Psychiatry. 2020 Jul 30;10(1):256. (PMID: 32732969)
Grant Information:
I 3875 Austria FWF_ Austrian Science Fund FWF
Contributed Indexing:
Keywords: anxiolytics; dentate gyrus; environmental enrichment; hippocampus; inflammation; innate anxiety; medial prefrontal cortex; microglia; stress; trait anxiety
Substance Nomenclature:
FYY3R43WGO (Minocycline)
Entry Date(s):
Date Created: 20221111 Date Completed: 20221114 Latest Revision: 20240417
Update Code:
20240417
PubMed Central ID:
PMC9657487
DOI:
10.3390/ijms232113052
PMID:
36361832
Czasopismo naukowe
Neuroinflammation is discussed to play a role in specific subgroups of different psychiatric disorders, including anxiety disorders. We have previously shown that a mouse model of trait anxiety (HAB) displays enhanced microglial density and phagocytic activity in key regions of anxiety circuits compared to normal-anxiety controls (NAB). Using minocycline, we provided causal evidence that reducing microglial activation within the dentate gyrus (DG) attenuated enhanced anxiety in HABs. Besides pharmacological intervention, "positive environmental stimuli", which have the advantage of exerting no side-effects, have been shown to modulate inflammation-related markers in human beings. Therefore, we now investigated whether environmental enrichment (EE) would be sufficient to modulate upregulated neuroinflammation in high-anxiety HABs. We show for the first time that EE can indeed attenuate enhanced trait anxiety, even when presented as late as adulthood. We further found that EE-induced anxiolysis was associated with the attenuation of enhanced microglial density (using Iba-1 as the marker) in the DG and medial prefrontal cortex. Additionally, EE reduced Iba1 + CD68+ microglia density within the anterior DG. Hence, the successful attenuation of trait anxiety by EE was associated in part with the normalization of neuro-inflammatory imbalances. These results suggest that pharmacological and/or positive behavioral therapies triggering microglia-targeted anti-inflammatory effects could be promising as novel alternatives or complimentary anxiolytic therapeutic approaches in specific subgroups of individuals predisposed to trait anxiety.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies